Basilea Pharmaceutica Ltd. (CH) - Basilea presents research data on a novel antibiotic at the Anti-Infectives Partnering & Deal-Making Summit
Basel, Switzerland, March 6, 2009 - Basilea's novel antibiotic BAL30072 demonstrates unrivalled activity against some of the most difficult to treat multi-resistant Gram-negative bacteria in in-vitro and in-vivo models of infection and addresses the emerging threat from multi-resistant Gram-negative bacteria
Basilea's Head of Biology, Prof. Malcolm Page, presents data on its novel antibiotic BAL30072 today at the 6th Anti-Infectives Partnering & Deal-Making Summit in Boston. BAL30072 has unrivalled activity against some of the most difficult-to-treat multi-resistant Gram-negative bacteria, such as Pseudomonas and Acinetobacter, both in susceptibility tests and in animal models of infection. BAL30072 has the potential to fill the treatment gaps of currently available antibiotics, such as the carbapenems.
BAL30072 is a novel siderophore monobactam that exploits the natural nutrient uptake like a trojan horse. Its unique pattern of penicillin-binding-protein inhibition and its bactericidal mode of action confer potent in-vitro and in-vivo activity against Gram-negative non-fermentors. These properties enable BAL30072 to overcome most of the genetically defined factors of beta-lactam resistance. In addition to the potent inhibition of Pseudomonas and Acinetobacter, BAL30072 also exhibits strong activity against Burkholderia spp. and Stenotrophomonas, two of the more difficult to treat Gram-negative pathogens.
Resistance rates are increasing among several problematic Gram-negative pathogens that are often responsible for serious hospital infections, including Acinetobacter spp. and Pseudomonas aeruginosa. They are associated with complicated urinary tract infections, nosocomial pneumonia (especially in ventilator-associated pneumonia and in patients with chronic obstructive pulmonary disease), complicated intra-abdominal infections and exacerbations of cystic fibrosis.
Infections caused by multi-resistant bacilli have been associated with prolonged hospital stays, higher healthcare costs and increased mortality, particularly when initial antibiotic therapy does not provide coverage of the causative pathogen. BAL30072 has the potential to become a unique, novel treatment option for these severe infections.
About Basilea Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX:BSLN). Basilea's integrated research and development operations are currently focused on new antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including two commercialized drugs (alitretinoin, ceftobiprole) and one investigational drug in phase III (isavuconazole). Toctino® (alitretinoin) is marketed in the United Kingdom, Denmark and Germany and is approved in Finland and France. Alitretinoin has been recommended for approval in six additional EU Member States and is under regulatory review in Canada and Switzerland. Furthermore a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Marketing applications for ceftobiprole (ZEFTERA(TM)/Zevtera(TM)) were submitted in the U.S., the EU and several other countries. The company has set up commercial organizations in UK, Denmark, Germany and Canada, while it is building sales and marketing organizations in other countries to commercialize alitretinoin and to co-promote ceftobiprole, subject to approval.
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact: Media Relations
Jean-Christophe Britt, Ph.D. Corporate Communication & Public Relations +41 61 606 1354
Barbara Zink, Ph.D., MBA Head Corporate Development +41 61 606 1233 email@example.com
Posted: March 2009